Molecular Basket Trial In Multiple Malignancies With Common Target Pathway Aberrancies: A Phase II Trial of GSK2256098 and Trametinib in Patients With Advanced Pancreatic Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 08 Feb 2018
At a glance
- Drugs GSK 2256098 (Primary) ; Trametinib (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 08 Feb 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 02 Feb 2018 Status changed from recruiting to active, no longer recruiting.
- 20 Jan 2018 Results assessing safety and efficacy presented at the 2018 Gastrointestinal Cancers Symposium